Secondary Logo

Most Popular Articles

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer

Owens, Gemma L.; Sheard, Victoria E.; Kalaitsidou, Milena; More

Journal of Immunotherapy. 41(3):130-140, April 2018.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

Lindenberg, Melanie A.; Retèl, Valesca P.; van den Berg, Joost H.; More

Journal of Immunotherapy. 41(9):413-425, November/December 2018.

Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy

Liu, Yanfen; Chen, Xinfeng; Wang, Dao; More

Journal of Immunotherapy. 41(9):406-410, November/December 2018.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

Fischer, Jeannette; Paret, Claudia; El Malki, Khalifa; More

Journal of Immunotherapy. 40(5):187-195, June 2017.

The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells

Merz, Christian; Sykora, Jaromir; Marschall, Viola; More

Journal of Immunotherapy. 41(9):385-398, November/December 2018.

A Clinical Development Paradigm for Cancer Vaccines and Related Biologics

Hoos, Axel; Parmiani, Giorgio; Hege, Kristen; More

Journal of Immunotherapy. 30(1):1-15, January 2007.

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

Dulos, John; Carven, Gregory J.; van Boxtel, Susan J.; More

Journal of Immunotherapy. 35(2):169-178, February-March 2012.

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient

Pollack, Seth M.; Lu, Hailing; Gnjatic, Sacha; More

Journal of Immunotherapy. 40(8):302-306, October 2017.

DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection

Chandra, Janin; Dutton, Julie L.; Li, Bo; More

Journal of Immunotherapy. 40(2):62-70, February/March 2017.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

Tavera, René J.; Forget, Marie-Andrée; Kim, Young Uk; More

Journal of Immunotherapy. 41(9):399-405, November/December 2018.

Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy

Keilholz, Ulrich; Weber, Jeffrey; Finke, James H.; More

Journal of Immunotherapy. 25(2):97-138, March-April 2002.

Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

Wang, Xiuli; Naranjo, Araceli; Brown, Christine E.; More

Journal of Immunotherapy. 35(9):689-701, November-December 2012.

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Nishida, Sumiyuki; Koido, Shigeo; Takeda, Yutaka; More

Journal of Immunotherapy. 37(2):105-114, February/March 2014.

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products

Nowicki, Theodore S.; Escuin-Ordinas, Helena; Avramis, Earl; More

Journal of Immunotherapy. 41(5):248-259, June 2018.

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial

Cohn, Allen; Morse, Michael A.; O’Neil, Bert; More

Journal of Immunotherapy. 41(3):141-150, April 2018.

Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class

Brischwein, Klaus; Parr, Larissa; Pflanz, Stefan; More

Journal of Immunotherapy. 30(8):798-807, November-December 2007.

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

Monk, Paul; Lam, Elaine; Mortazavi, Amir; More

Journal of Immunotherapy. 37(3):180-186, April 2014.

Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN

De Cesare, Michelandrea; Sfondrini, Lucia; Campiglio, Manuela; More

Journal of Immunotherapy. 33(1):8-15, January 2010.

Identification of a Novel Immunodominant HLA-B*07: 02-restricted Adenoviral Peptide Epitope and Its Potential in Adoptive Transfer Immunotherapy

Günther, Patrick S.; Peper, Janet K.; Faist, Benjamin; More

Journal of Immunotherapy. 38(7):267-275, September 2015.

Double-blind Placebo-controlled Study With Interleukin-18 and Interleukin-12-encoding Plasmid DNA Shows Antitumor Effect in Metastatic Melanoma in Gray Horses

Müller, Jessika- M.V.; Feige, Karsten; Wunderlin, Patrizia; More

Journal of Immunotherapy. 34(1):58-64, January 2011.

The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer Cell Cytotoxicity Against Melanoma Cell Lines In Vitro

Dupuis, Maria L.; Fiori, Valentina; Soriani, Alessandra; More

Journal of Immunotherapy. 38(9):357-370, November/December 2015.

The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

Guest, Ryan D; Hawkins, Robert E; Kirillova, Natalia; More

Journal of Immunotherapy. 28(3):203-211, May-June 2005.

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, Daniel; Stefanski, Jolanta; Przybylowski, Mark; More

Journal of Immunotherapy. 32(2):169-180, February-March 2009.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

Gangadhar, Tara C.; Hwu, Wen-Jen; Postow, Michael A.; More

Journal of Immunotherapy. 40(9):334-340, November/December 2017.

A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer

Prue, Rebecca L.; Vari, Frank; Radford, Kristen J.; More

Journal of Immunotherapy. 38(2):71-76, February/March 2015.

HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T Lymphocytes Display a Helper Activity for WT1-specific CTL Induction and a Cytotoxicity Against Leukemia Cells

Lin, Yuhung; Fujiki, Fumihiro; Katsuhara, Akiko; More

Journal of Immunotherapy. 36(3):159-170, April 2013.

Effective Clinical-scale Production of Dendritic Cell Vaccines by Monocyte Elutriation Directly in Medium, Subsequent Culture in Bags and Final Antigen Loading Using Peptides or RNA Transfection

Erdmann, Michael; Dörrie, Jan; Schaft, Niels; More

Journal of Immunotherapy. 30(6):663-674, September 2007.

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

Le, Dung T.; Lutz, Eric; Uram, Jennifer N.; More

Journal of Immunotherapy. 36(7):382-389, September 2013.

Show: